Skip to content

Since 1995, Defeat Duchenne Canada has built a foundation of strong partnerships with scientists and families who are dedicated to discovering treatments and a cure for Duchenne muscular dystrophy.

We believe in funding projects with the greatest chance of translating to clinical practice in a timely and cost-effective manner. This goal has brought us to granting $17.73 million, attracting applications from leading Duchenne researchers from around the world.

Research Grant Cycle Timeline

March 25: Our 2024 Research Grant Portal Opens

As part of our ongoing commitment to treating and improving the lives of those with Duchenne muscular dystrophy, we are funding more than $850,000 toward research in 2024, including previously funded researchers that are now completing years two and three of their projects.

Our 2024/2025 process will begin with a call for Letters of Intent (LOI) through our online grant portal beginning on March 25 2024, from investigators seeking funding for innovative projects.

Defeat Duchenne Canada invites research proposals focused on treating and improving the lives of individuals living with Duchenne muscular dystrophy. Successful proposals are expected to be of high scientific merit, demonstrate a clear, probable and timely path toward clinical implementation.

Priority will be given to projects that are cost effective and have the most significant impact on boys and young men living with Duchenne. Research groups funded by Defeat Duchenne Canada are highly encouraged to be open to collaboration with other investigators and to exploring additional partnerships with other foundations.

Click here to see the full list of funding criteria and conditions for 2024.

All applications will be reviewed by the organization’s funding advisory committees. Our Research Funding Advisory Committee (RFAC) comprised of researchers, clinicians, and scientists, and our Duchenne Family Advisory Committee (DFAC), including family members and individuals living with Duchenne muscular dystrophy. Defeat Duchenne Canada’s Board of Directors make the final funding decision based on the recommendations presented by both of these committees.

  1. Dr. Lisa Hoffman, RFAC Chair – Associate Scientist at the Lawson Health Research Institute, London, Ontario
  2. Dr. Hernan Gonorazky – Pediatric Neuromuscular Specialist and Scientist at the Hospital of Sick Children, Toronto, Ontario
  3. Dr. Hanns Lochmüller – Neuromuscular Specialist and Senior Scientist at the University of Ottawa, Ottawa, Ontario
  4. Dr. Jean Mah – Pediatric Neuromuscular Specialist and Senior Scientist at Alberta Children’s Hospital, Calgary, Alberta
  5. Dr. Toshifumi Yokota – Professor in the Department of Medical Genetics at the University of Alberta, Edmonton, Alberta
  1. Lorrie Power (NS) – Duchenne Family Advisory Committee Chair and Mother
  2. Kerri Denysiuk (SK) – Mother
  3. Kasha Mitton (BC) – Mother
  4. Nicole Mathison (SK) – Mother
  5. Darlene Morden (ON) – Mother
  6. Eric Morden (ON) – Young Adult with Duchenne
  7. Nicola Worsfold (ON) – Mother
  8. Rachael Prendergast (ON) – Mother

We are thankful for these exceptional volunteers who dedicate their time to this vital process. Their thought leadership enables us to decide where our donors’ generous gifts will make the most significant impact on the lives of those living with Duchenne.

The Application Process

Involves two stages of submission and review:

LOI’s will be rigorously reviewed by the organization’s Research Funding Advisory Committee (RFAC) and the Duchenne Family Advisory Committee (DFAC). All projects will be scored and shared between committees before final decisions are made. Proposals will be assessed based on defined criteria and conditions, as described above. Only a subset of applicants successful at accomplishing this first stage will then be invited to submit their full applications.

Selected applicants will be invited to submit full applications which will be rigorously reviewed once again by the organization’s Research Funding Advisory Committee (RFAC), Duchenne Family Advisory Committee (DFAC), and an outside expert reviewer(s) specific to each application. Final decisions on successful applications will be made by the Defeat Duchenne Canada’s Board of Directors.

The 2024 Research Grant Cycle will be open for Letters of Intent (LOI) starting March 25, 2024, closing on April 22, 2024.

For additional information or questions, please contact:

Lisa McCoy
Chief Executive Officer
Defeat Duchenne Canada
[email protected]

Dr. Lisa Hoffman
Research Funding Advisory Committee (RFAC) Chair
Associate Scientist
Lawson Health Research Institute (London, Ontario)
[email protected]

Funding Criteria for 2024

Click the button below to learn more about the funding criteria for 2024.

Research We Fund

Want to learn more about the research currently funded by Defeat Duchenne Canada?